CAPS Medical, of Netanya, Israel, closed a $3.5 million series A round led by Chasing Value Asset Management and the Los Angeles-based Israel Investment Fund Group. The new funds will be used to enable CAPS to undertake its first clinical trial for its minimally invasive, nonthermal plasma device for cancer treatment and further develop its portfolio for the treatment of solid tumors.
DNA Script SAS raised a $50 million extension to its series B financing, for a total yield of $89 million. Paris-based DNA Script has earmarked the funds to advance the development of its suite of enzymatic DNA synthesis (EDS) technologies and support the commercial launch of its Syntax DNA benchtop printer.
PERTH, Australia – Startup Inventia Life Science Pty. Ltd. has received two major investments from the Australian government to accelerate the development of a robotic device that prints a patient’s own skin cells directly onto a burn or wound. Named Ligō from the Latin “to bind,” the device could revolutionize the way surgeons approach wound repair.
Uncontrolled bleeding after giving birth is a common cause of severe maternal complications and even death, particularly in the U.S. and some developing nations. Alydia Health Inc. has developed a suction device that is placed in the uterus and is designed to halt hemorrhaging within a few minutes.